The Life Sciences team advised Royalty Pharma on its agreement to buy tiered, sales-based royalty rights on the global net sales of sacituzumab govitecan from Immunomedics for $175 million. Royalty Pharma has also agreed to purchase $75 million in common stock of Immunomedics.
Royalty Pharma is the industry leader in acquiring revenue-producing intellectual property, with over $15 billion in royalty assets. Royalty Pharma funds innovation in life sciences both directly and indirectly: directly when it partners with life sciences companies to co-develop and co-fund products in late-stage clinical trials, and indirectly when it acquires existing royalty interests from the original innovators.
For additional details on the transactions, please read the press release.